These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 27143379)

  • 1. [The effect of antioxidants on in vivo and in vitro methemoglobin formation in erytrocytes of patients with Parkinson`s disease].
    Makletsova MG; Rikhireva GT; Poleshuk VV; Grjakalov KV; Timerbaeva SL; Fedorova TN
    Biomed Khim; 2016; 62(2):193-7. PubMed ID: 27143379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitigation of Cu(II)-induced damage in human blood cells by carnosine: An in vitro study.
    Husain N; Mahmood R
    Toxicol In Vitro; 2020 Oct; 68():104956. PubMed ID: 32745495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The optimization of using levodopa in patients with Parkinson's disease: results of the OPTIMA study].
    Datieva VK; Makotrova TA; Levin OS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(10 Pt 2):13-9. PubMed ID: 23250605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Electron spin resonance studies on inhibiting methemoglobin in erythrocyte with exogenous ascorbic acid].
    Feng C; Hu X; Li J; He H
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2000 Dec; 17(4):487-9. PubMed ID: 11211848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of levodopa on thyroid function and prolactin release. A study in patients with Parkinson's disease.
    Lavin PJ; Gawel MJ; Das PK; Alaghband-Zadeh J; Rose FC
    Arch Neurol; 1981 Dec; 38(12):759-60. PubMed ID: 6797388
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
    Rinne UK; Rinne JO
    Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
    Kuoppamäki M; Leinonen M; Poewe W
    J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Estimating the potential of antioxidant therapy for patients with Parkinson's disease diagnosis].
    Katunina EA
    Eksp Klin Farmakol; 2005; 68(5):16-8. PubMed ID: 16277203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease.
    Martínez-Martín P; Hernández B; Ricart J;
    Neurologia; 2014 Apr; 29(3):153-60. PubMed ID: 23465686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effect of benzylpenicillin on the activity of antioxidative enzymes in the erythrocytes and on methemoglobin formation in children].
    Sal'nikova LA; Lopatina NI
    Antibiot Khimioter; 1989 Dec; 34(12):912-5. PubMed ID: 2629651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of NO-induced methemoglobinemia requires extremely high doses of ascorbic acid in vitro.
    Dötsch J; Demirakça S; Cryer A; Hänze J; Kühl PG; Rascher W
    Intensive Care Med; 1998 Jun; 24(6):612-5. PubMed ID: 9681784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.
    Waters CH; Nausieda P; Dzyak L; Spiegel J; Rudzinska M; Silver DE; Tsurkalenko ES; Kell S; Hsu A; Khanna S; Gupta S
    CNS Drugs; 2015 Apr; 29(4):341-50. PubMed ID: 25895021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clozapine in the treatment of adverse psychiatric manifestations of long-term therapy with levodopa].
    Svetel MV; Sternić NM; Filipović SR; Vojvodić NM; Kostić VS
    Srp Arh Celok Lek; 1997; 125(7-8):203-6. PubMed ID: 9304232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma homocysteine level and its relationship to clinical profile in Parkinson's disease patients at the Lagos University Teaching Hospital.
    Ojo OO; Oladipo OO; Ojini FI; Sanya EO; Danesi MA; Okubadejo NU
    West Afr J Med; 2011; 30(5):319-24. PubMed ID: 22752818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
    Podiwinsky F; Mentasti M; Riederer P; Birkmayer W
    Wien Klin Wochenschr; 1979 May; 91(10):332-7. PubMed ID: 452602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of vitamin C, deferoxamine, quercetin and rutin against tert-butyl hydroperoxide oxidative damage in human erythrocytes.
    Krukoski DW; Comar SR; Claro LM; Leonart MS; do Nascimento AJ
    Hematology; 2009 Jun; 14(3):168-72. PubMed ID: 19490763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.
    Solla P; Fasano A; Cannas A; Mulas CS; Marrosu MG; Lang AE; Marrosu F
    Parkinsonism Relat Disord; 2015 Aug; 21(8):968-71. PubMed ID: 26071817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations.
    Contin M; Lopane G; Passini A; Poli F; Iannello C; Guarino M
    Clin Neuropharmacol; 2015; 38(5):201-3. PubMed ID: 26366963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.